Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells

Oncogene volume 20, pages 8184–8192 (2001)Cite this article

Abstract

Cellular senescence has been proposed to be an in vitro and in vivo block that cells must overcome in order to immortalize and become tumorigenic. To characterize these pathways, we focused on changes in the cyclin-dependent kinase inhibitors and their binding partners that underlie the cell cycle arrest at senescence. As a model, we utilized normal human prostate epithelial cell (HPEC) and human uroepithelial cell (HUC) cultures. After 30–40 population doublings cells became growth-arrested in G0/1 with a threefold decrease in Cdk2-associated activity, a point defined as pre-senescence. Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated β-galactosidase (SA-β-gal). Levels of p16INK4a and p57KIP2 rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures. The induced expression of p57, similar to p16, produces a senescent-like phenotype. pRB, cyclin D, p19INK4d and p27KIP1 decrease in both cell types. We find that p53, p21CIP1 and p15INK4b are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence. Analysis of p53, p21CIP1, p15INK4b, p16INK4a, and p57KIP2 reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells. These results indicate: (i) the existence of a subset of growth inhibiting genes elevated at the onset of the senescence, (ii) a distinct class of genes involved in the maintenance of senescence, and (iii) the frequent inactivation of these pathways during immortalization.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Belair CD, Yeager TR, Lopez PM, Reznikoff CA . 1997 Proc. Natl. Acad. Sci. USA 94: 13677–13682

  • Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL . 1997 Cancer Res. 57: 995–1002

  • Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC . 1999 Exp. Cell. Res. 247: 168–175

  • Campisi J . 2000 In Vivo. 14: 183–188

  • Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB . 1999 Cancer Res. 59: 3761–3767

  • Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ . 1999 EMBO. J. 18: 1571–1583

  • Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE, Benson MC . 2000 Urology 56: 160–166

  • Dimri GP, Itahana K, Acosta M, Campisi J . 2000 Mol. Cell. Biol. 20: 273–285

  • Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J . 1995 Proc. Natl. Acad. Sci. USA 92: 9363–9367

  • Dyer MA, Cepko CL . 2000 Development 127: 3593–3605

  • England NL, Cuthbert AP, Trott DA, Jezzard S, Nobori T, Carson DA, Newbold RF . 1996 Carcinogenesis 17: 1567–1575

  • Fanton CP, McMahon M, Pieper RO . 2001 J. Biol. Chem. 276: 18871–18877

  • Fink JR, LeBien TW . 2001 Exp. Hematol. 29: 490–498

  • Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA . 1997 Genes Dev. 11: 2090–2100

  • Greenlee RT, Hill-Harmon MB, Murray T, Thun M . 2001 Ca Cancer J. Clin. 51: 15–36

  • Halbert CL, Demers GW, Galloway DA . 1991 J. Virol. 65: 473–478

  • Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G . 1996 Mol. Cell. Biol. 16: 859–867

  • Hayflick L . 1965 Exp. Cell. Res. 25: 585–621

  • Herman JG, Jen J, Merlo A, Baylin SB . 1996 Cancer Res. 56: 722–727

  • Itahana K, Dimri G, Campisi J . 2001 Eur. J. Biochem. 268: 2784–2791

  • Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA . 1999 Cancer Res. 59: 2957–2964

  • Kaelin Jr WG . 1999 Bioessays 21: 950–958

  • Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ . 1997 Cell 91: 649–659

  • Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL . 1997 Nat. Med. 3: 402–408

  • Lissy NA, Van Dyk LF, Becker-Hapak M, Vocero-Akbani A, Mendler JH, Dowdy SF . 1998 Immunity 8: 57–65

  • McConnell BB, Starborg M, Brookes S, Peters G . 1998 Curr. Biol. 8: 351–354

  • Morrison TB, Weis JJ, Wittwer CT . 1998 Biotechniques 24: 954–958, 960, 962

  • Nagahama H, Hatakeyama S, Nakayama K, Nagata M, Tomita K . 2001 Anat. Embryol. (Berl.) 203: 77–87

  • Nijjar T, Wigington D, Garbe JC, Waha A, Stampfer MR, Yaswen P . 1999 Cancer Res. 59: 5112–5118

  • Oya M, Schulz WA . 2000 Br. J. Cancer 83: 626–631

  • Pardee AB . 1989 Science 246: 603–608

  • Ran Q, Pereira-Smith OM . 2000 Exp. Gerontol. 35: 7–13

  • Reynaud EG, Leibovitch MP, Tintignac LA, Pelpel K, Guillier M, Leibovitch SA . 2000 J. Biol. Chem. 275: 18767–18776

  • Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, Thompson KJ, DeVries S, Bindley C, Newton MA et al. 1994 Genes Dev. 8: 2227–2240

  • Reznikoff CA, Johnson MD, Norback DH, Bryan GT . 1983 In Vitro 19: 326–343

  • Reznikoff CA, Loretz LJ, Pesciotta DM, Oberley TD, Ignjatovic MM . 1987 J. Cell. Physiol. 131: 285–301

  • Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM . 1996 Cancer Res. 56: 2886–2890

  • Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD . 2001 Nature 409: 633–637

  • Sandhu C, Peehl DM, Slingerland J . 2000 Cancer Res. 60: 2616–2622

  • Sarkar S, Julicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C, Jarrard DF, Reznikoff CA . 2000 Cancer Res. 60: 3862–3871

  • Sasaki M, Honda T, Yamada H, Wake N, Barrett JC, Oshimura M . 1994 Cancer Res. 54: 6090–6093

  • Savelieva E, Belair CD, Newton MA, DeVries S, Gray JW, Waldman F, Reznikoff CA . 1997 Oncogene 14: 551–560

  • Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . 1997 Cell 88: 593–602

  • Sherr CJ, DePinho RA . 2000 Cell 102: 407–410

  • Sherr CJ, Roberts JM . 1999 Genes Dev. 13: 1501–1512

  • Solomon MJ, Kaldis P . 1998 Results Probl. Cell. Differ. 22: 79–109

  • Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massague J, Hanel F, Eilers M . 2001 Nat. Cell. Biol. 3: 392–399

  • Tanaka H, Shimizu M, Horikawa I, Kugoh H, Yokota J, Barrett JC, Oshimura M . 1998 Genes Chromosomes Cancer 23: 123–133

  • Taniguchi T, Okamoto K, Reeve AE . 1997 Oncogene 14: 1201–1206

  • Tsugu A, Sakai K, Dirks PB, Jung S, Weksberg R, Fei YL, Mondal S, Ivanchuk S, Ackerley C, Hamel PA, Rutka JT . 2000 Am. J. Pathol. 157: 919–932

  • Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T, Haas M . 1998 Cell. Growth Differ. 9: 139–146

  • Weinberg RA . 1995 Cell 81: 323–330

  • Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP . 1997 Biotechniques 22: 130–131, 134–138

  • Xiong Y, Kuppuswamy D, Li Y, Livanos EM, Hixon M, White A, Beach D, Tlsty TD . 1996 J. Virol. 70: 999–1008

  • Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA . 1998 Genes Dev. 12: 163–174

  • Young JI, Smith JR . 2001 J. Biol. Chem. 276: 19610–19616

  • Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ . 1997 Nature 387: 151–158

Download references

Acknowledgements

This work was supported by National Institutes of Health number CA76184-01 and the University of Wisconsin Comprehensive Cancer Center.

Author information

Authors and Affiliations

  1. Department of Surgery, University of Wisconsin Comprehensive Cancer Center and the University of Wisconsin Medical School, Madison, WI 53972, Wisconsin, USA

    Steven R Schwarze, Yan Shi, Vivian X Fu & David F Jarrard

  2. Department of Oncology, University of Wisconsin Comprehensive Cancer Center and the University of Wisconsin Medical School, Madison, WI 53972, Wisconsin, USA

    Philip A Watson

  3. Department of Environmental Toxicology Center, University of Wisconsin Comprehensive Cancer Center and the University of Wisconsin Medical School, Madison, WI 53972, Wisconsin, USA

    David F Jarrard

Authors
  1. Steven R Schwarze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vivian X Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip A Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David F Jarrard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David F Jarrard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwarze, S., Shi, Y., Fu, V. et al. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20, 8184–8192 (2001). https://doi.org/10.1038/sj.onc.1205049

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205049

Keywords

This article is cited by

Search

Advanced search

Quick links